

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report: August 7, 2003

ACCESS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

DELAWARE 0-9314 83-0221517

(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)

2600 Stemmons Frwy. Suite 176, Dallas, TX 75207

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code (214) 905-5100

Not applicable

(Former name or former address; if changed since last report)

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

99.1 Access Pharmaceuticals, Inc. Press Release, dated August 6, 2003.

Item 9. Regulation FD Disclosure.

The following information is furnished pursuant to Item 12, "Disclosure of Results of Operations and Financial Condition."

Access Pharmaceuticals, Inc. issued a press release on August 6, 2003, a copy of which is attached as Exhibit 99.1 to this report and incorporated herein by this reference, in which it announced that on August 12, 2003 it will report its financial results for the second quarter ended June 28, 2003. It also announced that it will hold a conference call on August 12, 2003 to discuss the positive financial results, including that it has achieved its objective of being cash flow neutral, and other product developments. This information shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCESS PHARMACEUTICALS, INC.

Dated: August 7, 2003 By: /s/ Stephen B. Thompson

Stephen B. Thompson
Vice President and Chief Financial
Officer (Principal Financial and
Accounting Officer)

EXHIBIT INDEX

Exhibit Number	Description
-----	-----
99.1	Press Release, dated August 6, 2003

ACCESS
NEWS

Contact: Company

Contact: Investor Relations

Kerry P. Gray
President & CEO
(214) 905-5100

Donald C. Weinberger
Jeffrey Volk
Wolfe Axelrod
(212) 370-4500

Access Pharmaceuticals, Inc. Announces Conference Call for
Second Quarter Financial Results

DALLAS, TEXAS, August 6, 2003, ACCESS PHARMACEUTICALS, INC. (Amex: AKC) today announced that it will report its financial results for the second quarter ended June 30, 2003 before the market opens on Tuesday, August 12th. The announcement will be followed by a conference call at 11:00 am EDT to discuss the results, including the achievement of its objective of being cash flow neutral, as well as other positive financial and product developments at the Company. To participate please dial (800) 633-8514 about five to ten minutes prior to the initiation of the teleconference. The conference call will also be available on replay starting at 12:45 pm EDT on Tuesday, August 12th and ending at 12:45 pm EDT on Wednesday, August 13th. For the replay, please dial (800) 633-8284 (confirmation #21157624). The access number for the replay for international callers is (402) 977-9140 (confirmation # 21157624).

Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on developing both novel low development risk product candidates and technologies with longer-term major product opportunities. Access markets Aphthasol(R), the only FDA-approved product for the treatment of canker sores, and is developing products for mucositis and other dermatological indications. Access is also developing unique polymer platينات for use in the treatment of cancer and has developed, in conjunction with its partner Strakan, Ltd., the marketed product Zindaclin(R), which utilizes ResiDerm(R), our topical zinc delivery system that provides rapid delivery and reservoir of a drug in the skin. This press release contains certain statements that are forward-looking and that involve risks and uncertainties, including but not limited to the uncertainties associated with research and development activities, clinical trials, our ability to raise capital, the integration of acquired companies and technologies, the timing of and our ability to achieve regulatory approvals, dependence on others to market out licensed products, collaborations, future cash flow, the timing and receipt of licensing and milestone revenues, the future success of the Company's marketed products Aphthasol(R) and Zindaclin(R) and products in development including polymer platinate, OraDisc(TM) and our Mucositis technology, our ability to manufacture amlexanox products in commercial quantities, our sales projections and the sales projections of our licensing partners, our ability to achieve licensing milestones and other risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2002, and other reports filed by us with the Securities and Exchange Commission.